Adrenomedullin and Outcome in Severe Sepsis and Septic Shock
NCT ID: NCT02393781
Last Updated: 2016-06-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
596 participants
OBSERVATIONAL
2015-06-30
2016-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treatment of Patients With Early Septic Shock and Bio-Adrenomedullin(ADM) Concentration > 70 pg/ml With ADRECIZUMAB
NCT03085758
Bovine Intestinal Alkaline Phosphatase for the Treatment of Patients With Sepsis
NCT00430859
Examination of ADMA Serum Level and DDAH II
NCT01632059
Selepressin Evaluation Programme for Sepsis-Induced Shock - Adaptive Clinical Trial
NCT02508649
Dopexamine and Norepinephrine Compared With Epinephrine Alone in Septic Shock
NCT00134212
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In humans, plasma ADM has been determined only in a small number of sepsis patients, and - except from one study - the assays used did not selectively measure the bioactive ADM form and have been considered not reliable. Therefore, the potential value of determining plasma ADM in such patients cannot yet be ascertained and the optimal cut off needs to be validated in future studies
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients admitted in intensive care unit for severe sepsis or septic shock according to international, standardized criteria,transferred from another intensive care unit less than 24 hours after the primary admission, or being treated with vasopressors for less than 24 hours in the prior ICU
* Signed Consent form
Exclusion Criteria
* Severe sepsis or septic shock patients transferred from another intensive care unit later than 24 hours after the primary admission or being treated with vasopressors for more than 24 hours in the prior ICU
* Pregnant women
* Vegetative coma
* Participation in an interventional clinical trial in the preceding month
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fondation Transplantation_EDDH
UNKNOWN
Hopital Lariboisière
OTHER
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
OTHER
Sphingotec GmbH
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alexandre Mebazaa, Pr
Role: PRINCIPAL_INVESTIGATOR
Hôpital Lariboisière, France
Pierre François Laterre, Pr
Role: PRINCIPAL_INVESTIGATOR
Clinique Universitaire St Luc, Belgique
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cliniques Universitaires Saint-Luc
Brussels, , Belgium
CH Jolimont
La Louvière, , Belgium
Clinique St Pierre
Ottignies, , Belgium
Centre Hospitalier d'Angers
Angers, , France
Centre Hospitalier d'Angoulême
Angoulême, , France
Hopital Estaing
Clermont-Ferrand, , France
Hôpital Louis Mourier,
Colombes, , France
CHD de la Vendée
La Roche-sur-Yon, , France
CHU Dupuytren
Limoges, , France
Hôpital St Louis
Paris, , France
Hôpital Bichat Claude-Bernard
Paris, , France
Hôpital Lariboisière
Paris, , France
Nouvel Hôpital Civil
Strasbourg, , France
Hôpital de Hautepierre
Strasbourg, , France
CHRU Tours
Tours, , France
Klinik für Operative Intensivmedizin und Intermediate Care
Aachen, , Germany
Klinikum Augsburg
Augsburg, , Germany
Klinik für Anästhesiologie und Operative Intensivmedizin, Universitätsklinikum Köln
Cologne, , Germany
Klinik für Anästhesie, Intensivmedizin und Schmerztherapie, HELIOS-Klinikum Erfurt,
Erfurt, , Germany
Universitätsklinikum Jena
Jena, , Germany
Azienda Ospedaliera Sant'Andrea
Roma, , Italy
Policlinico Universitario A. Gemelli
Roma, , Italy
Medisch Spectrum Twente; Departement of Intensive Care
Enschede, Enschede, Netherlands
UMC Radboudziekenhuis, Dept. Intensive Care
Nijmegen, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Jolly L, Carrasco K, Salcedo-Magguilli M, Garaud JJ, Lambden S, van der Poll T, Mebazaa A, Laterre PF, Gibot S, Boufenzer A, Derive M. sTREM-1 is a specific biomarker of TREM-1 pathway activation. Cell Mol Immunol. 2021 Aug;18(8):2054-2056. doi: 10.1038/s41423-021-00733-5. Epub 2021 Jul 19. No abstract available.
Blet A, Deniau B, Santos K, van Lier DPT, Azibani F, Wittebole X, Chousterman BG, Gayat E, Hartmann O, Struck J, Bergmann A, Antonelli M, Beishuizen A, Constantin JM, Damoisel C, Deye N, Di Somma S, Dugernier T, Francois B, Gaudry S, Huberlant V, Lascarrou JB, Marx G, Mercier E, Oueslati H, Pickkers P, Sonneville R, Legrand M, Laterre PF, Mebazaa A; AdrenOSS-1 Study Investigators. Monitoring circulating dipeptidyl peptidase 3 (DPP3) predicts improvement of organ failure and survival in sepsis: a prospective observational multinational study. Crit Care. 2021 Feb 15;25(1):61. doi: 10.1186/s13054-021-03471-2.
Mebazaa A, Geven C, Hollinger A, Wittebole X, Chousterman BG, Blet A, Gayat E, Hartmann O, Scigalla P, Struck J, Bergmann A, Antonelli M, Beishuizen A, Constantin JM, Damoisel C, Deye N, Di Somma S, Dugernier T, Francois B, Gaudry S, Huberlant V, Lascarrou JB, Marx G, Mercier E, Oueslati H, Pickkers P, Sonneville R, Legrand M, Laterre PF; AdrenOSS-1 study investigators. Circulating adrenomedullin estimates survival and reversibility of organ failure in sepsis: the prospective observational multinational Adrenomedullin and Outcome in Sepsis and Septic Shock-1 (AdrenOSS-1) study. Crit Care. 2018 Dec 21;22(1):354. doi: 10.1186/s13054-018-2243-2.
Hollinger A, Wittebole X, Francois B, Pickkers P, Antonelli M, Gayat E, Chousterman BG, Lascarrou JB, Dugernier T, Di Somma S, Struck J, Bergmann A, Beishuizen A, Constantin JM, Damoisel C, Deye N, Gaudry S, Huberlant V, Marx G, Mercier E, Oueslati H, Hartmann O, Sonneville R, Laterre PF, Mebazaa A, Legrand M. Proenkephalin A 119-159 (Penkid) Is an Early Biomarker of Septic Acute Kidney Injury: The Kidney in Sepsis and Septic Shock (Kid-SSS) Study. Kidney Int Rep. 2018 Aug 22;3(6):1424-1433. doi: 10.1016/j.ekir.2018.08.006. eCollection 2018 Nov.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2014-A01906-41
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.